Recommendations
Key Recommendations
Benzodiazepine (BZD) overdose is usually determined by the patient's history, either from their own report, or by circumstantial evidence, such as BZD prescriptions or a history of psychiatric illness or previous overdose.
The key factors in making the diagnosis are signs and symptoms of central nervous system (CNS) inhibition, particularly drowsiness with unremarkable vital signs and no focal signs on neurologic exam.
Clinical evaluation
Ataxia and altered mental state are the most common features, but symptoms and signs may be nonspecific and highly variable. Typical signs of CNS depression include slurred speech, incoordination, unsteady gait, and impaired attention or memory, especially the loss of anterograde memory (patients should be asked about recent events since exposure, such as who brought them to hospital and how). Other physical signs may include nystagmus and decreased deep tendon reflexes. More subtle signs of impaired mental status include inappropriate behavior or judgment, and labile mood.
Overdose may also present with paradoxical stimulation, particularly in patients with psychiatric, hyperactive, or aggressive disorders.
Laboratory investigations
Initial tests to exclude other causes include a rapid bedside determination of glucose, pulse oximetry, complete blood count, serum chemistry panel, serum ethanol level, urine toxicology screen, and ECG. ECG can show abnormalities including transient first and second degree block and QT prolongation but investigations are otherwise usually normal in pure BZD overdose. Any abnormalities should prompt further investigations as appropriate. CNS depression can mirror respiratory depression; therefore, patients with deteriorating levels of consciousness should be closely observed for any deterioration in oxygen saturation.
In the acute overdose situation, most toxicologists suggest that BZD screening is not appropriate. Immunoassay screening tests for BZD that are typically used in emergency care settings have many false-positive and false-negative results; thus their use should be discouraged.[30] Most screening tests for BZD detect only certain metabolites of BZD (namely, desmethyldiazepam or oxazepam); hence, many BZDs are not routinely detected. Negative screening tests do not therefore exclude BZD overdose. Furthermore, because of the long half-life of many BZDs and their metabolites, a positive screening test may fail to differentiate between BZD use at some time in the past (sometimes even weeks previously) and acute overdose.
Healthcare professionals should take into consideration that fentanyl (an opioid analgesic) is an increasingly common cause of overdose, both with and without BZDs, but is not generally included on urine toxicology screens. In 2023, 70% of all BZD-involved deaths in the US also involved fentanyl.[14]
Use of this content is subject to our disclaimer